| Biosimilar name (active ingredient) | Reference biologic | Original approval date | Indications | Interchangeability |
|---|---|---|---|---|
| Abrilada (adalimumab-afzb) | Humira (adalimumab) | September 2016 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Amjevita (adalimumab-atto) | Humira (adalimumab) | September 2016 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Avsola (infliximab-axxq) | Remicade (infliximab) | December 2019 | RA, PsA, AS, CD, UC, PsO | No |
| Avtozma (tocilizumab-anoh) | Actemra (tocilizumab) | January 2025 | RA, GCA, PJIA, SJIA, COVID-19 | Yes |
| Cyltezo (adalimumab-adbm) | Humira (adalimumab) | August 2017 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Erelzi (etanercept-szzs) | Enbrel (etanercept) | August 2016 | RA, JIA, PsA, AS, PsO | No |
| Eticovo (etanercept-ykro) | Enbrel (etanercept) | April 2019 | RA, JIA, PsA, AS, PsO | Yes (only 25 mg/0.5 mL, 50 mg/mL) |
| Hadlima (adalimumab-bwwd) | Humira (adalimumab) | July 2019 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Hulio (adalimumab-fkjp) | Humira (adalimumab) | July 2020 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Hyrimoz (adalimumab-adaz) | Humira (adalimumab) | October 2018 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Idacio (adalimumab-aacf) | Humira (adalimumab) | December 2022 | RA, JIA, PsA, AS, CD, UC, PsO, HS, UV | No |
| Imuldosa (ustekinumab-srlf) | Stelara (ustekinumab) | October 2024 | PsO, PsA, CD, UC | No |
| Inflectra (infliximab-dyyb) | Remicade (infliximab) | April 2016 | RA, PsA, AS, CD, UC, PsO | No |
| Ixifi (infliximab-qbtx) | Remicade (infliximab) | December 2017 | RA, PsA, AS, CD, UC, PsO | No |
| Otulfi (ustekinumab-aauz) | Stelara (ustekinumab) | September 2024 | PsO, PsA, UC, CD | Yes |
| Pyzchiva (ustekinumab-sbdc) | Stelara (ustekinumab) | October 2023 | PsA, CD, UC, PsO | Yes |
| Renflexis (infliximab-abda) | Remicade (infliximab) | April 2017 | RA, PsA, AS, CD, UC, PsO | No |
| Riabni (rituximab-arrx) | Rituxan (rituximab) | December 2020 | RA, NHL, CLL, GPA, MPA, PV | No |
| Ruxience (rituximab-pvvr) | Rituxan (rituximab) | July 2019 | RA, NHL, CLL, GPA, MPA, PV | No |
| Selarsdi (ustekinumab-aekn) | Stelara (ustekinumab) | April 2024 | PsA, CD, UC, PsO | Yes |
| Simlandi (adalimumab-ryvk) | Humira (adalimumab) | February 2024 | RA, JIA, PsA, AS, CD, UC, PsO | Yes |
| Starjemza (ustekinumab-hmny) | Stelara (ustekinumab) | May 2025 | PsO, PsA, UC, CD | Yes |
| Steqeyma (ustekinumab-stba) | Stelara (ustekinumab) | December 2024 | PsO, PsA, CD, UC | Yes |
| Tofidence (tocilizumab-bavi) | Actemra (tocilizumab) | September 2023 | RA, GCA, PJIA, SJIA, COVID-19 | No |
| Truxima (rituximab-abbs) | Rituxan (rituximab) | November 2018 | RA, NHL, CLL, GPA, MPA | No |
| Tyenne (tocilizumab-aazg) | Actemra (tocilizumab) | March 2024 | RA, GCA, PJIA, SJIA, CRS, COVID-19 | No |
| Wezlana (ustekinumab-auub) | Stelara (ustekinumab) | October 2023 | PsO, PsA, CD, UC | Yes |
| Yesintek (ustekinumab-kfce) | Stelara (ustekinumab) | November 2024 | PsO, PsA, UC, CD | Yes |
| Yuflyma (adalimumab-aaty) | Humira (adalimumab) | May 2023 | RA, JIA, PsA, AS, CD, UV, PsO, HS | Yes |
| Yusimry (adalimumab-aqvh) | Humira (adalimumab) | December 2021 | RA, JIA, PsA, AS, CD, UC, PsO | No |
AS: ankylosing spondylitis; CD: Crohn’s disease; CLL: chronic lymphocytic leukemia; CRS: cytokine release syndrome; FDA: Food and Drug Administration; GCA: giant cell arteritis; GPA: granulomatosis with polyangiitis; HS: hidradenitis suppurativa; JIA: juvenile idiopathic arthritis; MPA: microscopic polyangiitis; MSD: musculoskeletal disease; NHL: non-Hodgkin’s lymphoma; PJIA: polyarticular juvenile idiopathic arthritis; PsA: psoriatic arthritis; PsO: plaque psoriasis; PV: pemphigus vulgaris; RA: rheumatoid arthritis; SJIA: systemic juvenile idiopathic arthritis; UC: ulcerative colitis; UV: urticarial vasculitis